Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer.
To reduce recurrence in the patients with bladder cancer after tumor removal through open surgery or transurethral resection, a form of gelatin-adriamycin sustained drug release system was developed and its release kinetics both in vitro and in vivo, its efficacy in inhibiting BIU-87 bladder tumor cell growth in vitro and its safety in vivo were studied. The results showed that this system controlled adriamycin release over a period of 21 days in vitro and significantly inhibited BIU-87 cell growth. When this system was injected into rabbit bladder, it sustained adriamycin release for 12 days and the released drug could diffuse 1 cm around the injection point. No major complications were observed except minor acute nonspecific cystitis that could be tolerated well by the animals. This study suggests the possibility of applying this system locally in treating bladder cancer.
Ye
Z
Z
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030.
Chen
J
J
Zhang
X
X
Li
J
J
Zhou
S
S
Yang
W
W
Zhang
Y
Y
D000283:Administration, Intravesical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000008:administration & dosage*; D005780:Gelatin / Q000008:administration & dosage; D006801:Humans; D011817:Rabbits; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004317:Doxorubicin; D005780:Gelatin